Lipase and amylase on GLP-1 therapy: the label numbers, the pancreatitis warning, and why routine testing is not asked for

Lipase and amylase are the pancreatic enzymes, and the pancreas is the organ people worry about on GLP-1 therapy. The worry has a real basis (pancreatitis is a warning on every label) and a common misreading (that a routine lipase would catch it early). The labels are unusually direct on this point, so this page mostly quotes them.

What the enzymes measure

Both are digestive enzymes made in the pancreas. When the pancreas is inflamed they leak into the blood. Lipase is the more specific of the two: MedlinePlus gives a common range of 0 to 160 U/L and lists pancreatitis, pancreatic or bile duct blockage, bowel obstruction, kidney failure and salivary gland inflammation among causes of a high result. Amylase is also made by the salivary glands, so it rises with mumps or a blocked salivary duct; MedlinePlus gives 40 to 140 U/L. Both pages carry the note that ranges vary by laboratory.

The label numbers

The labels report what happened to these enzymes in the trials, and they report it as averages across everyone treated, not as a rate of pancreatitis.

Wegovy (section 6.1): adult and pediatric patients treated with Wegovy had a mean increase from baseline in amylase of 15% to 16% and lipase of 39% in the weight-reduction trials; these changes were not observed in the placebo group. In the MASH trial, lipase increases greater than three times the upper limit of normal occurred in 4.7% (35 of 750) of Wegovy-treated patients versus 1.3% (5 of 374) on placebo.

Zepbound (section 6.1): in the pool of Studies 1 and 2, mean increases from baseline in pancreatic amylase of 20% to 25% and lipase of 28% to 35%, against 2.1% and 5.8% in placebo-treated patients.

Mounjaro (section 6.1): in the pooled placebo-controlled trials, mean increases in pancreatic amylase of 33% to 38% and lipase of 31% to 42%; placebo-treated patients had a 4% mean increase in amylase and no change in lipase.

Then the sentence all three labels share: the clinical significance of elevations in amylase or lipase with the drug is unknown in the absence of other signs and symptoms of pancreatitis.

The pancreatitis warning

Section 5.2 of the Wegovy label (5.5 in Zepbound's) says acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists. After initiation, observe patients carefully for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting. If pancreatitis is suspected, discontinue the drug and initiate appropriate management.

Notice what the instruction is: observe for symptoms. Not: measure lipase at intervals.

Why routine lipase is not asked for

Put the two label passages together and the logic is clear. On average, lipase goes up in treated people who are perfectly well. A routine lipase in someone without symptoms will therefore often come back above the range, and the label says nobody knows what that means. It cannot be used to decide anything, and it can trigger imaging and anxiety that lead nowhere. A lipase drawn in someone with persistent severe abdominal pain is a different test: there, a marked elevation supports the diagnosis and changes management.

We looked for a major clinical guideline recommending routine lipase or amylase monitoring in asymptomatic people on GLP-1 therapy and did not find one. If your prescriber includes a lipase in a baseline panel, that is their choice and gives a personal reference point; it is not a label requirement.

What the regulators concluded about pancreatic risk

In 2014 the FDA and the European Medicines Agency published a joint assessment of pancreatic safety for incretin-based drugs, after reviewing clinical trial data, animal toxicology and postmarketing reports. They concluded that the available data did not support a causal association between the drugs and pancreatitis or pancreatic cancer, while stating that a final conclusion could not be reached and that pancreatitis would continue to be considered a risk (Egan et al., N Engl J Med 2014). That position is why the warning stays on the label and why it is written as a symptom warning rather than a monitoring schedule.

Two things that change the calculation

A history of pancreatitis. The labels do not list prior pancreatitis as a contraindication, but it belongs in the first conversation with your prescriber, before the first dose. Prescribers weigh it differently, and some will want a baseline lipase and a lower threshold for investigation.

Gallstones. Gallstones are a leading cause of pancreatitis, and the labels report gallbladder disease as an adverse reaction of these drugs. The gallbladder page covers when imaging is done.

What to discuss with your prescriber

• Any past pancreatitis, heavy alcohol use or very high triglycerides (another pancreatitis cause).
• What abdominal pain should make you stop the drug and seek care the same day. The label language is the test: persistent or severe, possibly radiating to the back.
• If a lipase was drawn without symptoms and came back high: what, if anything, it changes.

Compounded semaglutide and tirzepatide, including products dispensed through FormBlends, are not FDA approved; the enzyme data above come from brand trials and the brand labels. For the practical side, the FormBlends GLP-1 overview and the Compounding Explained site cover what a compounded product is and is not.